Julie Dubourg

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 9

Top Topics

Top Venues

Nature medicine

Diabetes, obesity & metabolism

European journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Stephen A Harrison, Alina M Allen, Julie Dubourg, Mazen Noureddin, Naim Alkhouri
Challenges and opportunities in NASH drug development. Nature medicine 29 (3) (2023)
Stephen A Harrison, Alina M Allen, Julie Dubourg, Mazen Noureddin, Naim Alkhouri
Challenges and opportunities in NASH drug development. Nature medicine 29 (3) (2023)
Stephen A Harrison, Alina M Allen, Julie Dubourg, Mazen Noureddin, Naim Alkhouri
Challenges and opportunities in NASH drug development. Nature medicine (2023)
Stephen A Harrison, Julie Dubourg
Editorial: Liver hypercortisolism as a potential target for MASH treatment. Alimentary pharmacology & therapeutics 58 (11-12) (2023)
Caroline Reilhac, Julie Dubourg, Carole Thang, Jean-Marie Grouin, Pascale Fouqueray, Hirotaka Watada
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes, obesity & metabolism 24 (5) (2022)
Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean-Marie Grouin, Kohei Kaku
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial. Diabetes, obesity & metabolism (2021)
Julie Dubourg, Kohjiro Ueki, Jean-Marie Grouin, Pascale Fouqueray
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diabetes, obesity & metabolism 23 (3) (2021)
Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial. Diabetes care 44 (4) (2021)
Julie Dubourg, Sandrine Perrimond-Dauchy, Mathieu Felices, Sébastien Bolze, Pascal Voiriot, Pascale Fouqueray
Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. European journal of clinical pharmacology 76 (10) (2020)